Marshall Wace LLP Boosts Position in Fresenius Medical Care AG (NYSE:FMS)

Marshall Wace LLP raised its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 8.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 15,363 shares of the company’s stock after purchasing an additional 1,207 shares during the period. Marshall Wace LLP’s holdings in Fresenius Medical Care were worth $293,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Fresenius Medical Care by 21.8% during the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after purchasing an additional 758 shares during the period. ORG Partners LLC bought a new stake in shares of Fresenius Medical Care in the 1st quarter valued at about $110,000. SageView Advisory Group LLC bought a new stake in shares of Fresenius Medical Care in the 1st quarter valued at about $127,000. Signaturefd LLC boosted its holdings in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after buying an additional 672 shares in the last quarter. Finally, Caprock Group LLC bought a new stake in shares of Fresenius Medical Care in the 2nd quarter valued at about $208,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Performance

FMS opened at $19.60 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The firm has a fifty day moving average price of $19.82 and a 200 day moving average price of $20.03. Fresenius Medical Care AG has a 1 year low of $16.37 and a 1 year high of $22.76. The stock has a market cap of $11.50 billion, a P/E ratio of 20.25, a P/E/G ratio of 1.06 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.38. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. The firm had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Equities research analysts anticipate that Fresenius Medical Care AG will post 1.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research report on Tuesday. They set a “strong-buy” rating on the stock. Truist Financial upped their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Fresenius Medical Care currently has a consensus rating of “Hold” and an average price target of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.